ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 81

Preliminary Consensus Treatment Plans for Periodic Fever, Aphthous Stomatitis, Pharyngitis and Adenitis: The Foundation for Capturing Treatment Responses in PFAPA from the CARRA PFAPA Subcommittee

Gil Amarilyo1, Deborah Rothman2, Kalpana Manthiram3, Suzanne Li4, Liora Harel5, Kathryn Edwards6, Gary Marshall7, Simona Nativ8, Kathleen Haines9, Geraldina Lionetti10, Julie Cherian11, Yongdong Zhao12, Patricia DeLaMora13, Grant Syverson14, Ian Michelow15, Yuriy Stepanovskiy16, Akaluck Thatayatikom17, Cagri Yildirim-Toruner18, Shoghik Akoghlanian19, Lori Tucker20, Katalin Koranyi19, Hemaltha Srinivasalu21, Fatma Dedeoglu22 and Sivia Lapidus8, 1Schneider Children's Medical Center of Israel, Sackler School of Medicine, Tel Aviv University, Petach Tikva, Israel, 2Albany Medical Center, Albany, NY, 3National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, 4Pediatrics, Joseph M Sanzari Children’s Hospital, Hackensack Meridian Health, Hackensack, NJ, 5Schneider Children's Medical Center of Israel, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel, 6Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, TN, 7Norton Children's Hospital, University of Louisville, Louisville, KY, 8Pediatric Rheumatology, Goryeb Children's Hospital, Morristown, NJ, 9Joseph M Sanzari Children’s Hospital, Hackensack Meridian Health, Hackensack, NJ, 10Pediatric Rheumatology, UCSF Benioff Children's Hospital Oakland, Oakland, CA, 11Department of Pediatrics, Stony Brook University Hospital, Stony Brook, NY, 12Seattle Children's Hospital, Department of Pediatric Rheumatology, University of Washington, Seattle, WA, 13Weill Cornell Medical College, New York, NY, 14Pediatric Rheumatology, Medical College of Wisconsin, Wauwatosa, WI, 15Center for International Health Research, Alpert Medical School of Brown University, Providence, RI, 16Shupyk National Academy of Postgraduate Education, Kyiv, Ukraine, 17UF Health Shands Hospital, Gainesville, FL, 18Rheumatology, Nationwide Children's Hospital, Columbus, OH, 19Nationwide Children's Hospital, Columbus, OH, 20Pediatric Rheum/Rm K4-120, BC Childrens Hospital, Vancouver, BC, Canada, 21Children's National Medical Center, Washington, DC, 22Division of Immunology, Rheumatology Program, Boston Children's Hospital, Harvard Medical School, Boston, MA

Meeting: 2017 Pediatric Rheumatology Symposium

Keywords: Fever

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Thursday, May 18, 2017

Title: Clinical and Therapeutic Poster Session

Session Type: Abstract Submissions

Session Time: 5:30PM-7:00PM

Background/Purpose: PFAPA is the most common recurrent fever condition in children.  A recent survey showed heterogeneity in physicians’ management strategies.  In order to evaluate the effectiveness of different treatments for PFAPA, standardized treatment plans are needed.  The PFAPA Work Group of CARRA (Childhood Arthritis and Rheumatology Research Alliance) developed CTPs for PFAPA that will lead to improved characterization of a well-defined cohort and optimal treatment. We aimed to develop consensus treatment plans (CTPs) for periodic fever, aphthous stomatitis, pharyngitis and adenitis (PFAPA) syndrome for future evaluation of treatment responses in PFAPA.

Methods: A core group of  PFAPA experts including pediatric rheumatologists, infectious disease specialists and immunologists comprised the CARRA PFAPA Workgroup.  After a literature review was conducted, a survey was distributed to pediatric rheumatology and infectious diseases physicians who treat PFAPA patients to query their management strategies. The CARRA PFAPA workgroup met monthly via teleconferences and in-person meetings from 2014-2016 to develop the CTPs. A modified nominal group technique was employed to create the proposed CTPs.   Patient characteristics for enrollment were established through expert consensus.

Results: Based on these data, 4 preliminary CTP arms were created: anti-pyretic treatment, corticosteroids, prophylaxis arm and surgical management (Figure 1).  This approach was approved by the majority of the PFAPA subcommittee. 

Conclusion: CTPs with four treatment arms were developed for PFAPA. Coupled with data collection on patient outcomes at defined intervals, these CTPs will generate comparative effectiveness data in an observational setting to determine optimal treatment of PFAPA after the larger CARRA group is assessed for their willingness to follow at least one of the regimens in these CTPs.

 

Antipyretic arm,Cimetidine 10-20mg/kg/dose twice a day ,Prophylaxis arm,Colchicine 0.5-1.25mg/day ,Fever interval ≤ 14 days,Incomplete response*,* Incomplete response defined as recurrence of fever within 12-24 hours after treatment with prednisone Recommended time trial for medication efficacy is 3 months or 3 febrile episodes before changing to another arm.

 

 

 

 

 

 

 

 

 

 

 

Figure 1


Disclosure: G. Amarilyo, 2,5; D. Rothman, None; K. Manthiram, None; S. Li, None; L. Harel, 2,5; K. Edwards, None; G. Marshall, None; S. Nativ, 5; K. Haines, None; G. Lionetti, None; J. Cherian, None; Y. Zhao, 2; P. DeLaMora, None; G. Syverson, None; I. Michelow, None; Y. Stepanovskiy, None; A. Thatayatikom, None; C. Yildirim-Toruner, None; S. Akoghlanian, None; L. Tucker, None; K. Koranyi, None; H. Srinivasalu, None; F. Dedeoglu, None; S. Lapidus, 5.

To cite this abstract in AMA style:

Amarilyo G, Rothman D, Manthiram K, Li S, Harel L, Edwards K, Marshall G, Nativ S, Haines K, Lionetti G, Cherian J, Zhao Y, DeLaMora P, Syverson G, Michelow I, Stepanovskiy Y, Thatayatikom A, Yildirim-Toruner C, Akoghlanian S, Tucker L, Koranyi K, Srinivasalu H, Dedeoglu F, Lapidus S. Preliminary Consensus Treatment Plans for Periodic Fever, Aphthous Stomatitis, Pharyngitis and Adenitis: The Foundation for Capturing Treatment Responses in PFAPA from the CARRA PFAPA Subcommittee [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 4). https://acrabstracts.org/abstract/preliminary-consensus-treatment-plans-for-periodic-fever-aphthous-stomatitis-pharyngitis-and-adenitis-the-foundation-for-capturing-treatment-responses-in-pfapa-from-the-carra-pfapa-subcommittee/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 Pediatric Rheumatology Symposium

ACR Meeting Abstracts - https://acrabstracts.org/abstract/preliminary-consensus-treatment-plans-for-periodic-fever-aphthous-stomatitis-pharyngitis-and-adenitis-the-foundation-for-capturing-treatment-responses-in-pfapa-from-the-carra-pfapa-subcommittee/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology